June 4, 2025
Press Release
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
April 3, 2025
Press Release
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
January 22, 2025
Press Release
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
January 8, 2025
Press Release
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
October 8, 2024
Press Release
Vividion Therapeutics Appoints Frank Poschen to Board of Directors
